- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.05. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | ProKidney GAAP EPS of -$0.13, revenue of $0.2M | 1 | Seeking Alpha | ||
| 12.05. | PROKIDNEY CORP. Loss At -$16.73 Mln In Q1 | 1 | RTTNews | ||
| 12.05. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | ProKidney Reports First Quarter 2025 Financial Results and Business Highlights | 319 | GlobeNewswire (Europe) | Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional... ► Artikel lesen | |
| 12.05. | PROKIDNEY CORP. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.03. | PROKIDNEY CORP. - S-4, Registration of securities, business combinations | 1 | SEC Filings | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 20.03. | PROKIDNEY CORP. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 10-K, Annual Report | 2 | SEC Filings | ||
| 17.03. | PROKIDNEY CORP. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | ProKidney GAAP EPS of -$0.62 | 2 | Seeking Alpha | ||
| 17.03. | PROKIDNEY CORP. Full Year Loss Increases | - | RTTNews | ||
| 17.03. | ProKidney Reports Full Year 2024 Financial Results and Business Highlights | 138 | GlobeNewswire (Europe) | Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing... ► Artikel lesen | |
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 144 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 276 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen | |
| 10.06.24 | ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates | 191 | GlobeNewswire (Europe) | Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
| INOVIO PHARMACEUTICALS | 1,980 | -0,50 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,342 | -0,58 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2025 Financial Results | CAMBRIDGE, Mass., May 13, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,115 | -100,00 % | Enveric Biosciences, Inc. - 8-K, Current Report | ||
| VERRICA PHARMACEUTICALS | 0,535 | 0,00 % | Verrica Pharmaceuticals Inc. - 8-K, Current Report | ||
| REPARE THERAPEUTICS | 1,470 | -1,34 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| BIOATLA | 0,480 | +5,08 % | BioAtla reports promising trial results for cancer drug | ||
| RELMADA THERAPEUTICS | 0,720 | -2,04 % | Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase... ► Artikel lesen | |
| BOUNDLESS BIO | 1,180 | +1,29 % | Boundless Bio, Inc.: Boundless Bio Announces Portfolio Prioritization and Runway Extension | Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 7,250 | -0,34 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported | 15 patients treated across four escalating dose levels of TTX-MC138
No significant safety or dose limiting toxicities reported
10 patients remain on study with... ► Artikel lesen | |
| PEPGEN | 1,485 | +4,58 % | PepGen Inc. hält Jahreshauptversammlung, wählt Direktoren und bestätigt Wirtschaftsprüfer | ||
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen |
Das Unternehmen PROKIDNEY CORP kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,173 (+21,98 %) liegt der Kurs bei 0,960 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.